Safety of COVID-19 Vaccines During Pregnancy: A Short Communication

R. Vijayan, A. Senatus, Swostik Pradhananga, C. Kamwal, Madiha Zaidi, A. Choudhry, S. A. Hassan, Marcos Sanchez Gonsalez, M. Díaz, Efrain Garcia
{"title":"Safety of COVID-19 Vaccines During Pregnancy: A Short Communication","authors":"R. Vijayan, A. Senatus, Swostik Pradhananga, C. Kamwal, Madiha Zaidi, A. Choudhry, S. A. Hassan, Marcos Sanchez Gonsalez, M. Díaz, Efrain Garcia","doi":"10.33425/2639-9458.1128","DOIUrl":null,"url":null,"abstract":"Background: COVID-19 a novel viral infection has taken many lives worldwide in a very short period. The first case of SARS CoV-2 was reported in December 2019 in Wuhan, China. The number of infected cases subsequently increased, leading to a pandemic declaration by WHO in March 2020. Several clinical trials are currently underway to produce effective vaccines to fight against this virus; however, a few of them include pregnant women; leaving us to question the efficacy of the vaccine. Pregnant women are immune-compromised and considered a high-risk group for SARS-CoV-2 and therefore experience maternal and fetal consequences. It seems to be essential to incorporate them in these clinical trials. This study was led to understand the factors preventing pregnant women from participating in such trials and to assess the safety of potential COVID-19 vaccines during pregnancy. Methods: This study was conducted using the available literature was done in May 31 2021 by searching databases: PubMed, WHO, clinicaltrials.gov and Google Scholar. Keywords such as COVID-19 Vaccine, COVID Vaccine Clinical Trials, COVID prevention in pregnancy, and their combinations were used. We included patients with a positive COVID-19 test and excluded systematic reviews on COVID-19 negative pregnant patients. The search was comprehensive according to the cross-checking of reference lists from the articles retrieved. Results: Our search results led to 4320 studies after removing duplicates; title and abstract screening were done for 20 studies. We also performed the manual search to look for related articles and 13 studies were included in the final analysis. Conclusion: To enable and ameliorate the participation of pregnant and lactating women for the development of vaccines against COVID-19, we are left with a question pertaining to the short as well as long term prognosis of COVID-19 in pregnant women, their fetus, and also the infants. With such approach we can establish and enable a proper guidance and framework to emphasize the inclusion of pregnant women in the development of future vaccine.","PeriodicalId":93597,"journal":{"name":"Microbiology & infectious diseases (Wilmington, Del.)","volume":" ","pages":""},"PeriodicalIF":0.0000,"publicationDate":"2021-08-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Microbiology & infectious diseases (Wilmington, Del.)","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.33425/2639-9458.1128","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 0

Abstract

Background: COVID-19 a novel viral infection has taken many lives worldwide in a very short period. The first case of SARS CoV-2 was reported in December 2019 in Wuhan, China. The number of infected cases subsequently increased, leading to a pandemic declaration by WHO in March 2020. Several clinical trials are currently underway to produce effective vaccines to fight against this virus; however, a few of them include pregnant women; leaving us to question the efficacy of the vaccine. Pregnant women are immune-compromised and considered a high-risk group for SARS-CoV-2 and therefore experience maternal and fetal consequences. It seems to be essential to incorporate them in these clinical trials. This study was led to understand the factors preventing pregnant women from participating in such trials and to assess the safety of potential COVID-19 vaccines during pregnancy. Methods: This study was conducted using the available literature was done in May 31 2021 by searching databases: PubMed, WHO, clinicaltrials.gov and Google Scholar. Keywords such as COVID-19 Vaccine, COVID Vaccine Clinical Trials, COVID prevention in pregnancy, and their combinations were used. We included patients with a positive COVID-19 test and excluded systematic reviews on COVID-19 negative pregnant patients. The search was comprehensive according to the cross-checking of reference lists from the articles retrieved. Results: Our search results led to 4320 studies after removing duplicates; title and abstract screening were done for 20 studies. We also performed the manual search to look for related articles and 13 studies were included in the final analysis. Conclusion: To enable and ameliorate the participation of pregnant and lactating women for the development of vaccines against COVID-19, we are left with a question pertaining to the short as well as long term prognosis of COVID-19 in pregnant women, their fetus, and also the infants. With such approach we can establish and enable a proper guidance and framework to emphasize the inclusion of pregnant women in the development of future vaccine.
妊娠期新冠肺炎疫苗的安全性:一个简短的沟通
背景:新冠肺炎是一种新型病毒感染,在很短的时间内夺走了世界各地许多人的生命。2019年12月,中国武汉报告了首例严重急性呼吸系统综合征冠状病毒2型病例。感染病例数随后增加,导致世界卫生组织于2020年3月宣布大流行。目前正在进行几项临床试验,以生产有效的疫苗来对抗这种病毒;然而,其中少数包括孕妇;让我们不得不质疑疫苗的有效性。孕妇免疫受损,被认为是严重急性呼吸系统综合征冠状病毒2型的高危人群,因此会经历母婴后果。将它们纳入这些临床试验似乎是至关重要的。这项研究旨在了解阻止孕妇参与此类试验的因素,并评估潜在新冠肺炎疫苗在妊娠期间的安全性。方法:本研究使用2021年5月31日通过搜索数据库进行的现有文献:PubMed、世界卫生组织、clinicaltrials.gov和Google Scholar。使用了新冠肺炎疫苗、新冠肺炎疫苗临床试验、妊娠期新冠肺炎预防及其组合等关键词。我们纳入了新冠肺炎检测呈阳性的患者,并排除了对新冠肺炎阴性孕妇的系统评价。根据对检索到的文章的参考文献列表的交叉检查,搜索是全面的。结果:我们的搜索结果在删除重复项后导致4320项研究;对20项研究进行了标题和摘要筛选。我们还进行了手动搜索以查找相关文章,最终分析中包括13项研究。结论:为了使孕妇和哺乳期妇女能够更好地参与新冠肺炎疫苗的开发,我们面临的问题是孕妇、胎儿和婴儿新冠肺炎的短期和长期预后。有了这种方法,我们可以建立并启用一个适当的指导和框架,以强调孕妇参与未来疫苗的开发。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
自引率
0.00%
发文量
0
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:604180095
Book学术官方微信